Nasdaq · Biotech stocks database

GYRE — Gyre Therapeutics Inc.

GYRE (Gyre Therapeutics Inc.) stock: $7.42, $827.4M market cap, $57.3M cash, $770.1M EV, $966.5M fully diluted market cap. Data from Fully Diluted's biotech stocks database.

Share price

$7.42

Market cap

$827.4M

Cash

$57.3M

Enterprise value

$770.1M

Balance sheet

Cash	$57.3M
Debt	$0.0M
Net cash	$57.3M
Enterprise value	$770.1M
Basic shares	106.0M shares
Fully diluted shares	130.3M shares
Fully diluted market cap	$966.5M
Cash per share	$0.54

Cash figures as of 2026-06-30. Database snapshot: 2026-09-22.

Price history

Loading GYRE daily closes…

Loading price history…

Pipeline assets

F351

Phase 3 · Active Modality: small molecule (structurally modified pirfenidone derivative)

Aliases hydronidone

Target TGF-beta1 signaling pathway

Partnerships GNI Japan / GNI Group: Hydronidone IP rights for mainland China (right of first offer for global); RMB 8.3M on NDA inspection pass + RMB 49.6M on NMPA approval; 12 annual royalties (8-16% of sales)

Indications

Chronic hepatitis B (CHB)-associated liver fibrosis (PRC) (Phase 3)
MASH-associated liver fibrosis (U.S.) (Phase 1)

Status note Lead candidate. Pivotal Phase 3 in CHB liver fibrosis met primary and key secondary endpoints (May 2025); NMPA granted priority review (Mar 2026), NDA submitted Mar 22, 2026 and accepted May 12, 2026 (conditional approval sought); Phase 3C confirmatory trial underway. U.S. MASH program: Phase 1 in healthy volunteers completed, IND discussions with FDA ongoing for Phase 2.

ETUARY

Approved · Active Modality: small molecule

Aliases pirfenidone

Target TGF-β1; TNF-α

Indications

Idiopathic pulmonary fibrosis (IPF) (Approved)
Pneumoconiosis (PRC) (Phase 3)
Radiation-induced lung injury (RILI) (Phase 2/3)

Status note First-in-class PRC approval 2011; National Reimbursement Drug List 2017; leading PRC market position. Pneumoconiosis 52-week Phase 3 enrolled 272 patients (2025). RILI adaptive Phase 2/3 initiated April 2026.

Etorel

Approved · Active Modality: small molecule

Aliases nintedanib ethanesulfonate soft capsules

Partnerships Jiangsu Wangao Pharmaceuticals: drug registration certificate and marketing authorization holder transfer (May 2024)

Indications

IPF / SSc-ILD / progressive pulmonary fibrosis (PPF) (Approved)

Status note Commercial sales in the PRC commenced June 2025.

Contiva

Approved · Active

Aliases avatrombopag maleate

Target thrombopoietin receptor

Indications

Thrombocytopenia in chronic liver disease (adults undergoing elective procedures) (Approved)
Chronic immune thrombocytopenia (ITP) (Approved)

Status note Commercial product; no pipeline disclosure in excerpts.

CG001419

Phase 1 · Active Modality: targeted protein degrader (oral)

Target TRKA (tropomyosin receptor kinase A)

Indications

Pain (non-opioid) (Phase 1)
Solid tumors (TRK gene abnormalities) (Phase 1)

Status note Acquired via Cullgen. Phase 1 in 78 healthy volunteers completed Dec 2025 (Australia); Phase 1 in solid tumors ongoing in China.

CG009301

Phase 1 · Active Modality: targeted protein degrader

Target GSPT1

Indications

High-risk hematologic malignancies (including AML) (Phase 1)

Status note Acquired via Cullgen. Phase 1 dose-escalation in China initiated April 2025.

F573

Phase 2 · Active

Target caspases

Indications

Acute / acute-on-chronic liver failure (ALF/ACLF) (Phase 2)

Status note Phase 1 in healthy volunteers (PRC) completed; multi-stage Phase 2 initiated March 2023.

F230

Phase 1 · Active Modality: small molecule

Target Endothelin receptor A

Indications

Pulmonary arterial hypertension (PAH) (Phase 1)

Status note Selective endothelin receptor A antagonist. IND approved by NMPA May 2024; first subject enrolled in Phase 1 June 2025.

F528

Preclinical · Active Modality: anti-inflammatory small molecule

Target multiple inflammatory cytokines

Indications

Chronic obstructive pulmonary disease (COPD) (Preclinical)

Catalysts

— 2026

Status note Designed to inhibit multiple inflammatory cytokines; IND to NMPA anticipated in 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

No specialist-fund holders in 13F data for this company.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego

← GTBP All 714 biotech stocks HALO →

Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.